The serotonin pathway has been implicated in nicotine dependence and may influence smoking cessation. Therefore, 792 cigarette smokers from the Patch in Practice trial were genotyped for the tryptophan hydroxylase (TPH1 A779C), serotonin transporter (SLC6A4 5-HTTLPR), and 5-HT 1A (HTR1A C-1019G) polymorphisms. Cox regression analysis did not demonstrate significant effects of any of the three genotypes on relapse to smoking: TPH1 (Reference AA; AC: hazard ratio ( .58, p = 1.00). These data do not support a statistically or clinically significant moderating effect of these specific 5-HT pathway genetic variants on smoking cessation. However, the possibility remains that other variants in these or other 5-HT genes may influence NRT efficacy for smoking cessation in treatment seeking smokers.
Introduction
With converging data from multiple lines of investigation, it has become clear that nicotine dependence (ND) is under genetic influence (Li et al., 2003; Munafò et al., 2004) , and that subgroups defined by sex and genotype (David et al., 2007a,c; Johnstone et al., 2004; Lerman et al., 2003 Lerman et al., , 2006a Malaiyandi et al., 2006) may derive differential efficacy from pharmacological smoking cessation therapies. Based on the neurobiology of reward and the pharmacokinetics of nicotine, the predominance of research into genetic influences on tobacco use has focused on the dopamine (DA) and oxidative hepatic nicotine metabolism pathways [(i.e., cytochrome P450 (CYP2A6) ] . Despite mixed results and frequent lack of replication in case-control studies of some smoking-related phenotypes (e.g., smoking initiation, persistence, cigarettes/day) , some relatively consistent findings are emerging regarding the influence of genetic variants in the DA pathway (e.g., ANKK1, COMT) and CYP2A6 for treatment response to sustained-release bupropion (David et al., 2007a; Lerman et al., 2003; Swan et al., 2005) and nicotine replacement therapy (NRT) Lerman et al., 2006b) . However, few pharmacogenetic smoking cessation studies have investigated serotonergic candidate genes.
Centrally, tryptophan enters neurons via active transport and is converted by tryptophan hydroxylase (TPH) to 5-hydroxytryptophan and then decarboxylated to 5-hydroxytryptamine (serotonin; 5-HT) (Rang et al., 2003) . The conversion of tryptophan to 5-HT by TPH is the rate-limiting step in 5-HT synthesis. Nicotine administration stimulates release of 5-HT in the dorsal raphe nucleus (DRN) ). When 5-HT is released in the DRN, it binds to inhibitory 5-HT 1A autoreceptors , which appear to mediate synaptic release of 5-HT in terminal fields including the ventral striatum (Sprouse and Aghajanian, 1987) and hippocampus (Balfour et al., 1986a,b; Benwell and Balfour, 1979; Benwell et al., 1990) . Tryptophan depletion and neurotoxic 5-HT depletion are associated with increased compulsive use of drugs of abuse including nicotine in rats (Engel et al., 1992; Roberts et al., 1994) . Pharmacological 5-HT depletion and stimulation of 5-HT 1A receptors induce behavioral sensitization to nicotine (Olausson et al., 1999 (Olausson et al., , 2001a , while interventions that enhance 5-HT neurotransmission decrease compulsive drug use of amphetamine (Porrino et al., 1989) , heroin (Higgins et al., 1994 ), alcohol (LeMarquand et al., 1994 , and nicotine (Opitz and Weischer, 1988) ; and 5-HT 1A receptor stimulation inhibits behavioral sensitization to nicotine (Olausson et al., 1999 (Olausson et al., , 2001a and may mediate nicotine withdrawal symptoms (Cheeta et al., 2000 Engberg et al., 2000; Irvine et al., 2001; Mihailescu et al., 2001; Olausson et al., 2001b; Tucci et al., 2003) .
In humans, tryptophan depletion is associated with increased smoking intensity and desire to smoke (Hitsman et al., 2005) , higher attentional salience to smoking cues (Hitsman et al., 2007) , and higher negative affect in smokers; however, conversely, while pharmacological interventions that increase synaptic 5-HT -such as use of SSRIs -are efficacious for treatment of depression, meta-analyses of the use of serotonergic medications including SSRIs and buspirone (5-HT 1A agonist) have not demonstrated robust evidence of efficacy for smoking cessation (Hughes et al., 2000) . Finally, nicotine-induced 5-HTx-DA interactions contribute to neuroadaptations throughout the extended amygdala (Balfour, 2002; Olausson et al., 2002) . Thus, converging data from animal and human studies suggest that TPH, the 5-HT transporter, and 5-HT 1A receptors are important neurological substrates for nicotine dependence.
Two genes have been identified that code for TPH (TPH1; TPH2), both of which code for different isoforms of the TPH enzyme with differential expression in the brain (Abumaria et al., 2008) and somatic tissues (Walther et al., 2003) . The only published genetic association studies of nicotine dependence have examined variants in TPH1 (11p15.3-p14; GeneID: 7166)-which is approximately 20,000 base-pairs (bp) and contains 10 exons. Primarily two variants (C218A, A779C; both within intron 7) of the TPH1 gene have been the subject of multiple studies. The C218A and A779C are in tight linkage disequilibrium and have been associated with reduced levels of cerebrospinal fluid 5-hydroxyindoleacetic acid (a metabolite of 5-HT) (Nielsen et al., 1994) and with impulsive and aggressive traits, suicide, and alcoholism (Chung et al., 2005; Nielsen et al., 1998) and smoking behavior (David et al., 2007b; Lerman et al., 2001; Reuter and Hennig, 2005; Sullivan et al., 2001 ).
The 5-HTT gene (SLC6A4; 17q11.1-q12; Gene ID: 6532) is approximately 38,000 bp, is composed of 14 exons and encodes a transmembrane transporter responsible for reuptake of serotonin at the synapse and regulation of the magnitude and duration of serotonergic signaling. A 44 bp insertion/deletion polymorphism located approximately 1000 bp from transcription initiation site of the SLC6A4 gene results in a polymorphism known as the serotonin transporter gene-linked polymorphic region (5-HTTLPR) . The 5-HTTLPR short (S) allele is associated with decreased expression of the SLC6A4 gene relative to the long (L) form, and S allele carriers (SS or SL) genotypes have been associated with relatively decreased reuptake of 5-HT from the medium in vitro (Heils et al., 1997; Lesch et al., 1996; Little et al., 1998) and reduced 5-HT 1A binding potential in vivo (David et al., 2005) . The 5-HTTLPR has been associated with anxiety-related and compulsive behavior traits (Bengel et al., 1999; Munafò et al., 2003; Sen et al., 2004) , suicide (Du et al., 1999) , and greater attention to smoking-related cues (Munafò et al., 2005a) . There are three additional variants in untranslated regions of the SLC6A4 gene in the promoter which may affect its expression (Lasky-Su et al., 2005; Murphy et al., 2004) . However, to our knowledge, only the 5-HTTLPR has demonstrated associations with smoking-related phenotypes (Lerman et al., 2000; Munafò et al., 2004 Munafò et al., , 2005a .
The gene encoding 5-HT 1A receptor proteins (HTR1A; 5q11.2-q13; Gene ID: 3350), consists of 1268 bp and is without introns. The HTR1A gene codes for a G-protein coupled receptor with seven transmembrane domains (Wu and Comings, 1999) . There are at least nine single nucleotide polymorphisms (SNPs) present in the HTR1A gene, but only one SNP appears to be common in Europeans (C-1019G) (David et al., 2005) . The HTR1A-1019G allele has been associated with decreased transcriptional efficiency (Lemonde et al., 2003) , anxiety and depression (Lemonde et al., 2003; Strobel et al., 2003) , schizophrenia, substance use disorder, and panic attacks (Huang et al., 2004) , and there have been mixed results in terms of association with suicide.
Therefore, converging evidence from animal, preclinical and clinical human studies indicates that the 5-HT pathway is implicated in nicotine dependence-potentially contributing to neuroadaptations that moderate behavioral sensitization to nicotine, nicotine-induced alterations in mood, and nicotine withdrawal (Balfour, 2002; Cheeta et al., 2000 Cheeta et al., , 2001 Engberg et al., 2000; Irvine et al., 2001; Mihailescu et al., 2001; Olausson et al., 2001b; Tucci et al., 2003) . Furthermore, TPH enzymes, 5-HTTs, and 5-HT 1A receptors compose an integrated circuit that regulates synaptic 5-HT throughout the mesocorticolimbic system and functional genetic variants in the genes that encode these proteins have been identified (i.e., TPH1 A779C, SLC6A4 5-HTTLPR, HTR1A C-1019G) and thus they are strong candidates for examining smoking-related phenotypes. To date however, there have been only two other pharmacogenetic studies of genes in the serotonin (5-HT) pathway and both studies included only one genetic variant (5-HTTLPR) (David et al., 2007b; Munafò et al., 2006) ; moreover neither study demonstrated significant main effects or interactions with NRT for smoking cessation.
We hypothesized that genotypes associated with reduced synaptic 5-HT activity would be associated with greater efficacy of NRT for smoking cessation, given the theoretical need to self-medicate nicotine withdrawal (Lerman et al., 1996) , and therefore wished to explore whether this larger sample size of treatment seeking smokers might provide evidence for a small effect of 5-HTTLPR and other 5-HT pathway genotypes (i.e., TPH1 A779C, HTR1A C-1019G) on smoking cessation. In addition, we sought to examine whether we could detect main effects of genotype on smoking cessation by pooling data from all extant pharmacogenetic trials of NRT incorporating serotonergic genotypes.
Materials and methods

Patch in Practice study
2.1.1. Participants. Participants were eligible if they were aged 18 years and over and smoked 10 cigarettes/day or more, and were recruited from 26 general practices in Buckinghamshire and Oxfordshire in the United Kingdom (UK). Physicians recruited patients attending for other reasons (N = 60, 6.5%), or patients volunteered having seen posters or heard about the study (N = 15, 1.6%), while in some practices every registered smoker was contacted offering trial entry (N = 850, 91.9%). Blood samples were successfully collected and DNA extracted on N = 908 (98%) participants at trial entry. All participants provided informed consent prior to being included in the study. Ethical approval was obtained from the relevant local Research Ethics Committees at the University of Oxford and the University of Pennsylvania.
Treatment.
Participants were randomly assigned to one of two levels of smoking cessation behavioral support: usual care or recommended best practice, the latter typically including a higher level of support than is usually offered in primary care in the United Kingdom. In addition, all participants received 8 weeks of 15 mg nicotine replacement therapy transdermal patch. The details and results of the main trial are reported elsewhere (Aveyard et al., 2007) .
Participants were visited at 1 week, 2 weeks and 4 weeks from quit day to provide ongoing smoking cessation support and to assess smoking status, which was verified by exhaled carbon monoxide (CO) monitoring. Participants were phoned at 12 weeks, 26 weeks, and 52 weeks from quit day to assess smoking status, and those claiming at least 7-day abstinence were posted a saliva collection device to measure salivary cotinine.
Assessments.
2.1.3.1. Demographics. Self-reported sex, ancestry, and age were assessed at a baseline interview 2.1.3.2. Smoking cessation outcomes. Abstinence was defined as continuous confirmed abstinence at 12 and 26-weeks from start of treatment. Two standard definitions of abstinence have been proposed (Hughes et al., 2003; West et al., 2005) , which recommend a 2-week grace period at the beginning of cessation, during which lapses to smoking do not count against abstinence. Confirmation of abstinence was defined as an exhaled CO less than 10 parts per million (ppm), or salivary cotinine concentration less than 15 ng/ml on each occasion (Society for Research on Nicotine and Tobacco, 2002) . Participants who were withdrawn (which was commonly due to reverting to smoking) or who were lost to followup (unless they moved to an untraceable address or had died) were counted as smokers, as is standard (West et al., 2005) .
Nicotine dependence.
Nicotine dependence severity was assessed with the Fagerström Test of Nicotine Dependence (FTND) (Heatherton et al., 1991) , which is a validated, 6-item self-reported measure of nicotine dependence.
2.1.3.4.
Genotyping. Blood samples were processed upon receipt or after overnight storage at 4 • C (up to a maximum of 7 days after collection depending on delivery method to laboratory). Whole blood was separated by centrifugation and DNA immediately extracted from buffy coat lymphocytes using a standard salting out procedure (Miller et al., 1988) . Plasma was stored at −80 • C until required for analysis. Participants were genotyped for the 5-HTTLPR polymorphism, described in detail elsewhere (Munafò et al., 2005b) and briefly here. Genotyping for the TPH1 A779C (Lerman et al., 2001 ) and HTR1A C-1019G polymorphisms was completed using methods described below.
Oligonucleotide primers flanking the 5-HTTLPR from the SLC6A4 gene (GenBank accession number X76753) were used to amplify the DNA template using allele-specific PCR (Munafò et al., 2005b ) and the amplified product resolved by agarose gel electrophoresis and stained with ethidium bromide. This enabled determination of the long (L: 528 bp) and/or short (S: 484 bp) allele in each individual. Genotyping for TPH1 A779C and 5HT1A C-1019G was completed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Warrington, UK). Each Taqman reaction was performed using 10 ng DNA, 2.5 l of 2× ABI Taqman Universal Mastermix, 0.375 l water, and 0.125 l of 40× Assay by Design SNP assay for the relevant gene target. Primers and probes for Taqman assays are shown in Table 1 . The 5 l reactions were performed in a 384-well plate (Abgene, Epsom, UK). Thermal cycling was completed in a MJ Research PTC225 Tetrad DNA engine (GRI, Braintree, UK) using the following conditions: (1) activation of reaction mix with a 50 • C hold for 2 min, (2) denaturation for 10 min at 95 • C, 40 cycles of 95 • C for 15 s and 60 • C for 1 min and (3) 4 • C hold. The plates were scanned using the ABI Prism 7900HT Allelic Discrimination End-Point analysis and data were analysed by the SDS V1.2 software (Applied Biosystems, Warrington, UK). The assays were initially validated by 48 samples of European origin. Two investigators blinded to subject smoking cessation outcomes reviewed PCR results independently. Munafò et al. (2006) , was conducted using samples from N = 393 smokers of European ancestry who participated in a randomized clinical trial of transdermal nicotine patch vs. nicotine nasal spray for 8 weeks of treatment. Participants were recruited from Washington, DC and Philadelphia, PA, USA in a study conducted at the University of Pennsylvania (UPenn trial). Additional details of this study design have been previously reported (Lerman et al., 2006a) . Verification of abstinence was confirmed by exhaled carbon monoxide (<10 ppm) at the end of treatment (EOT) and 6-month follow-ups. The mean age of participants was 46 years 7 months (standard deviation (S.D.) = 11 years 5 months; range = 20-78 years) and 47% of participants were female. Of the 393 participants randomized to nicotine nasal spray or transdermal patch, confirmed abstinence data was available for 182 smokers randomized to NRT patch who were of European ancestry.
Pooled analysis of PiP
The second study, by David et al. (2007b) , included N = 741 smokers of European ancestry from the Patch II trial who participated in a double-blind, randomized, placebo-controlled trial of the nicotine transdermal patch between June 1991 and March 1992 (the Patch II trial) (Imperial Cancer Research Fund General Practice Research Group, 1993 and were re-contacted in 1999-2000 for DNA collection. Participants were recruited from general practice surgeries in Oxfordshire, UK. The duration of treatment with active nicotine (N = 341) and placebo patches (N = 340) was 12 weeks. Details regarding the Patch II trial (Imperial Cancer Research Fund General Practice Research Group, 1993 , and the 8-year follow-up (Patch II study) have been comprehensively described elsewhere Yudkin et al., 2003 Yudkin et al., , 2004 . The mean age of participants was 42 years 11 months (S.D. = 9 years (CC, CG or GG) were entered into the model, controlling for the effects of age, FTND and time spent using NRT, since not all participants used the full course of NRT that they were prescribed. The genotype-x-sex and genotype-x-genotype interaction terms were each tested and removed if non-significant, in which case the effect of sex was controlled.
Pooled analyses.
Next, binary logistic regression analysis of the PiP study participants combined with samples from the UPenn and Patch II trials was performed using biochemically verified point prevalence of abstinence at end of treatment and 26-week follow-up. Data were not available for days of continuous abstinence from all three studies and therefore survival analyses could not be performed with the pooled data. There were 845 participants of European ancestry with point prevalence data available from the PiP trial, which were combined with data from the UPenn trial (N = 182) and the Patch II trial (N = 371) for a pooled sample size of N = 1398. All analyses were conducted using the Statistical Software for the Social Sciences (v. 12.0) (SPSS Inc., Chicago, IL). An α level of 0.05 was maintained throughout the analyses.
Statistical power
The sample size of the PiP Study is adequate to detect an OR of 1.8 for TPH1 A779C, 1.6 for 5-HTTLPR, and 2.2 for HTR1A C-1019G at α = 0.05 and power of 80% for main effects of genotype on 12-week abstinence outcomes using binary logistic regression. When the samples from the PiP, UPenn, and Patch II trials are combined, the sample size is more than sufficient to detect an OR of 1.4 for association of 5-HTTLPR with smoking cessation at α = 0.05, and power of 80%. (Aveyard et al., 2007) of which N = 908 (98%) provided a DNA sample and N = 886 were successfully genotyped for all three (TPH1 A779C, 5-HTTLPR and HTR1A C-1019G) genetic variants. Nicotine dependence data were missing in 70 participants. Of the remaining 816 participants, 792 were of European ancestry and had complete data at all time points-thus constituting our final study sample. Basic characteristics and genotype frequencies for the study participants can be seen in Table 2 . Frequencies for each genetic variant did not deviate from Hardy-Weinberg Equilibrium (χ 2 < 2.5; ps > 0.1). There was no evidence of interaction effects between any of the genotypes, or between the genotypes and sex. Nicotine dependence = Fagerström Test of Nicotine Dependence (Heatherton et al., 1991) . S.D. = standard deviation.
Results
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CI 0.63, 1.58, p = 1.00). The sex-x-genotype study-x-genotype interaction terms were non-significant at both time points. The main effect of study was also significant at both time points, reflecting lower abstinence rates in the larger studies (PiP and Patch II). These results did not alter substantially when point prevalence abstinence data were analysed. Abstinence rates stratified by genotype for all three studies are presented in Table 3 .
Discussion
Despite the putative role of 5-HT in nicotine dependence, our pharmacogenetic analyses do not suggest that any of the three specific genetic variants from the 5-HT pathway (TPH1 C779A, 5-HTTLPR, HTR1A C-1-19G) exert a substantial influence on smoking cessation outcomes in patients seeking treatment with NRT. There are a number of possible explanations for why these candidate genes produced null results.
These data do not preclude moderating effects of other polymorphisms in the TPH1, SLC6A4 or HTR1A genes on smoking cessation. First, without fine-grained SNP mapping of the TPH1, HTR1A, and SLC6A4 genes it is possible that other genetic variants associated with NRT efficacy for smoking cessation may be present but were not included in our analyses. Secondly, the phenotypes for which significant associations between 5-HT pathway genes have been demonstrated are very different constructs from NRT efficacy for smoking cessation per se even though such phenotypes frequently co-occur with nicotine dependence. For example, the TPH1 C779A polymorphism has been associated with smoking initiation (Sullivan et al., 2001 ) and age of onset of smoking (Lerman et al., 2001) , and the 5-HTTLPR has been associated with selective processing of smoking-related cues (Munafò et al., 2005a) or traits that frequently co-occur with smoking such as anxiety traits, mood disorders, and alcohol consumption (Curran et al., 2005; Lasky-Su et al., 2005; Lesch et al., 1996; Munafò et al., 2005b; Murphy et al., 2004) . Likewise, there are no published studies demonstrating associations between the HTR1A gene and smoking-related traits, even though the HTR1A C-1019G polymorphism has been associated depression, anxiety-related and depression-related traits, and substance use disorder (Huang et al., 2004; Lemonde et al., 2003; Strobel et al., 2003) .
Previous studies demonstrating significant associations with smoking cessation on NRT have incorporated genes within the dopamine pathway and the CYP2A6 gene-candidate genes whose role is directly or indirectly related to nicotine administration. There is as yet no evidence indicating that 5-HT neurotransmission is a critical neurological substrate for the process of smoking cessation per se or for a putative role in suppressing nicotine withdrawal in smokers administered NRT. Although our results do not support a moderating role of these specific serotonergic candidate gene variants on smoking cessation in treatment seeking smokers using NRT, it remains to be seen whether or not these genetic variants influence the efficacy of other agents such as SSRIs for smoking cessation, which have been associated with decreased craving and negative affect during quit attempts and may portend a modest benefit for Table 3 Abstinence data from the PiP, UPenn and Patch II trials by 5-HTTLPR genotype 17 (55%) 21 (29%) 54 (13%) 50 (53%) 41 (24%) 25 (10%) 25 (45%) 31 (25%) 54 (20%) 145 (21%) 81 ( 14 (45%) 51 (71%) 372 (87%) 45 (47%) 132 (76%) 225 (90%) 31 (55%) 95 (75%) 218 (80%) 549 (79%) 351 ( 15 (21%) 38 (9%) 35 (37%) 30 (17%) 21 (8%) 20 (37%) 30 (24%) 38 (14%) 103 (15%) 71 ( 19 (66%) 57 (79%) 388 (91%) 60 (63%) 143 (83%) 229 (92%) 34 (63%) 96 (76%) 232 (86%) 591 (85%) 359 ( smoking cessation (Cook et al., 2004; Killen et al., 2000; Niaura et al., 2002) . Indeed, Killen et al. (2000) demonstrated that paroxetine reduced tobacco craving, and Cook et al. (2004) observed that fluoxetine was associated with lower negative and positive affect during periods of abstinence in smokers undergoing quit attempts. Therefore, to date, there is no evidence to support a substantial influence of serotonergic genotypes on NRT efficacy for smoking cessation. The present study (PiP) represents the largest within-treatment pharmacogenetic study of NRT to date (N = 792), and the pooled analyses the largest sample size yet reported for analyses of pharmacogenetic smoking cessation studies utilizing repeated-measures clinical trial data with biochemical verification of abstinence (N = 1398). Despite adequate power to detect a modest effect size in the pooled analyses, there was no evidence for association between the 5-HTTLPR and smoking cessation. Given the statistical power of the pooled analyses, if an association exists between the 5-HTTLPR and smoking cessation, any effect would likely be a small one (OR < 1.4), consistent with evidence for the effects of other single gene polymorphisms on behavioral phenotypes.
The prospect of potentially tailoring NRT based on serotonergic genotypes appears unlikely to materialize. Nevertheless, it has yet to be established whether or not genetic variation in the 5-HT pathway influences smoking cessation efficacy for other pharmacological agents. It remains a possibility that serotonergic pharmacotherapies such as SSRIs or buspirone, which have not demonstrated efficacy for smoking cessation may be efficacious for subgroups defined by genetic variants in the 5-HT pathway. There is currently no evidence suggesting a genetic influence on serotonergic agents for smoking cessation and thus this remains a potential area for future research.
In conclusion, pharmacogenetic analyses of three key 5-HT pathway genotypes failed to detect associations with smoking cessation in a practice-based clinical trial of NRT. In the one candidate gene variant with data available in other pharmacogenetic studies (5-HTTLPR), pooled analyses of three studies, including new data presented here, demonstrated no significant association with smoking cessation at either end of treatment or 6 months. As these data represent all known pharmacogenetic datasets of 5-HT genotypes in clinical trials of NRT, and are robust when combining three independent samples from the U.S. and the U.K., the results add to a growing body of literature suggesting that genetic variation in the 5-HT pathway is unlikely to serve an important role in the moderation of treatment response to NRT for smoking cessation.
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